Haleon PLC Sponsored ADR $HLN Shares Sold by Acumen Wealth Advisors LLC

Acumen Wealth Advisors LLC decreased its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 25.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 291,363 shares of the company’s stock after selling 99,258 shares during the period. Acumen Wealth Advisors LLC’s holdings in Haleon were worth $2,917,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in HLN. Parkside Financial Bank & Trust lifted its position in Haleon by 101.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock valued at $29,000 after buying an additional 1,433 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC boosted its position in shares of Haleon by 402.0% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after buying an additional 2,404 shares during the period. Geneos Wealth Management Inc. boosted its holdings in Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after acquiring an additional 1,203 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in Haleon by 428.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock valued at $57,000 after acquiring an additional 5,124 shares during the period. Finally, Assetmark Inc. grew its position in Haleon by 26.6% in the 4th quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock valued at $60,000 after acquiring an additional 1,252 shares in the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy”.

Haleon Price Performance

Haleon stock opened at $9.94 on Wednesday. The stock has a market cap of $43.76 billion, a P/E ratio of 25.47, a price-to-earnings-growth ratio of 2.32 and a beta of 0.13. The company has a fifty day simple moving average of $9.31 and a 200-day simple moving average of $9.86. Haleon PLC Sponsored ADR has a 12-month low of $8.65 and a 12-month high of $11.28. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.